Publication | Closed Access

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

Hematological MalignancyMomelotinib VersusSimplify 2HematologyPharmacotherapyMedicineAvailable TherapyMyeloid Neoplasia